Lim Sung Yoon, Kim Myung Gyu, Park Kwon Tae, Jung Cheol Woong
Department of Internal Medicine, Korea University Medical College, Seoul, Korea.
Department of Surgery, Korea University Medical College, Seoul, Korea.
Ann Surg Treat Res. 2017 May;92(5):361-364. doi: 10.4174/astr.2017.92.5.361. Epub 2017 Apr 27.
Routine evaluation of kidney donors occasionally reveals an incidental renal mass with an otherwise satisfactory kidney function. The use of such a kidney with an enhancing mass for transplantation is a matter of debate owing to a possible risk of transmission of donor malignancies. We report our experience of kidney transplants from donors with renal cell carcinoma, after resection of the renal mass.
Two women aged 44 and 56 years were diagnosed with enhancing renal masses measuring 0.9 cm and 0.7 cm, respectively, during donor evaluation for kidney transplantation. Both patients and their families were informed of a potential risk of recurrent renal cell carcinoma following transplantation.
Renal function test results of both donors satisfied the living donor selection criteria. Laparoscopic live donor nephrectomy was performed with resection of renal masses on the bench table. Immediate pathological analysis revealed a renal cell carcinoma with a margin of normal renal parenchyma before transplantation. Regimens based on mammalian target of rapamycin inhibitors, which are known for their antitumoral properties, were used for immunosuppression in both recipients. None of the recipients showed recurrence or metastasis during the follow-up period, which was longer than 3 years after transplantation.
In light of the ongoing shortage of kidney donors, kidneys with small renal cell carcinoma could be considered for transplantation after appropriate removal of the lesion, with a very low risk of recurrent disease.
对肾供体进行常规评估时,偶尔会发现附带肾肿物但肾功能其他方面令人满意的情况。由于存在供体恶性肿瘤传播的潜在风险,使用有强化肿物的肾脏进行移植存在争议。我们报告了在切除肾肿物后,使用患有肾细胞癌的供体进行肾移植的经验。
在对两名年龄分别为44岁和56岁的女性进行肾移植供体评估期间,分别诊断出大小为0.9厘米和0.7厘米的强化肾肿物。已将移植后肾细胞癌复发的潜在风险告知了这两名患者及其家属。
两名供体的肾功能测试结果均符合活体供体选择标准。在手术台上切除肾肿物后,进行了腹腔镜活体供肾切除术。即刻病理分析显示移植前为肾细胞癌且切缘有正常肾实质。两名受者均采用了以具有抗肿瘤特性而闻名的雷帕霉素靶蛋白抑制剂为基础的免疫抑制方案。在移植后超过3年的随访期内,所有受者均未出现复发或转移。
鉴于肾供体持续短缺,在适当切除病变后,可考虑使用患有小肾细胞癌的肾脏进行移植,疾病复发风险极低。